Announcements Trials
Browse Landscape

Phase

Phase 4 3Phase 1 3Phase NA 2Phase 2 2Phase 1/2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 11Thoracic 10Tumor-Agnostic 9Lymphoid 5Dermatologic 5Breast 5Genitourinary 3CNS 3Gastrointestinal 2Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Head & Neck 1Gynecologic 1Endocrine 1

Conditions

Prostatic Neoplasms 1Prostate Cancer Patients 1Pharmacokinetics of MDV3100 1

Interventions

pembrolizumab 93Nivolumab 61Docetaxel 55Cyclophosphamide 49enzalutamide 44Magnetic Resonance Spectroscopy 33Ipilimumab 33Gemcitabine 32Abiraterone Acetate 30Prednisone 29fludarabine 28Everolimus 27Paclitaxel 25Cisplatin 24Radiotherapy 23Carboplatin 23Sunitinib 22cabozantinib 21atezolizumab 20Radiosurgery 20Specimen Handling 19Sorafenib 18Bevacizumab 18pazopanib 17bicalutamide 17abiraterone 17Biopsy 15temsirolimus 14darolutamide 14apalutamide 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Midazolam × Genitourinary × Clear all
NCT04676035 2023-02-09

The DDI Study Had Been Designed to Investigate the Effect of SHR3680 on the Pharmacokinetics of Midazolam, S-Warfarin and Omeprazole

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
18 enrolled
Genitourinary

Prostate Cancer Patients

NCT03237416 2018-11-06

Drug-drug-interaction Study to Assess the Effect of Darolutamide on the Pharmacokinetics of Probe Substrates of CYP3A4 and P-gp in Healthy Male Volunteers

Bayer

Phase 1 Completed
15 enrolled
Genitourinary

Prostatic Neoplasms

NCT01911728 2017-06-26

Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates

Astellas Pharma Inc

Phase 1 Completed
14 enrolled
Genitourinary

Pharmacokinetics of MDV3100

Data powered by HemOnc (CC BY 4.0) Colophon âš¡